May 13, 2020
QurAlis officially launches under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis (ALS) and genetically related frontotemporal dementia (FTD).
November 19, 2018
QurAlis raises a $5,500,000 seed round from BioInnovation Capital.
QurAlis raises a $5,500,000 seed round from Amgen Ventures, BioInnovation Capital, MP Healthcare Venture Management and Viva Biotech Limited.
QurAlis Raises $5.5 Million Seed Round
Documentaries, videos and podcasts
Viva Biotech Holdings
March 10, 2021
/PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including...
July 1, 2020
In May, startup QurAlis got a $42 million series A toward targeting the genetic causes of two rare diseases: amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
May 13, 2020
QurAlis has officially launched under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.